

Correction: Characterization of chimeric antigen receptor modified T cells expressing scFv-IL-13Rα2 after radiolabeling with ⁸⁹Zirconium oxine for PET imaging



Pamela Leland^{1^}, Dhiraj Kumar², Sridhar Nimmagadda², Steven R. Bauer^{1,3}, Raj K. Puri^{1,4} and Bharat H. Joshi^{1*}

Correction: Journal of Translational Medicine (2023) 21:367 https://doi.org/10.1186/s12967-023-04142-2

Following publication of the original article [1], we have been notified that the legend order of X axis in Fig. 7 was incorrect. The corrected x-axis legend Fig. 7 is given below:

Published online: 19 September 2023

[†]Deceased—Pamela Leland.

The online version of the original article can be found at https://doi.org/10. 1186/s12967-023-04142-2.

*Correspondence:

Bharat H. Joshi

bharat.joshi@fda.hhs.gov

¹ Tumor Vaccines and Biotechnology Branch, Division of Cellular and Gene Therapies, Office of Tissues and Advance Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA

² Department of Radiology and Radiological Science, Johns Hopkins

University School of Medicine, Baltimore, MD, USA

³ Present Address: Wake Forest Institute of Regenerative Medicine,

Winston Salem, NC, USA

⁴ Present Address: Iovance Biotherapeutics, San Carlos, CA, USA



This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativeco mmons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/ zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.



Fig. 7 ⁸⁹Zr-oxine radiolabeling did not interfere with the biological functional potency of CAR-T cells. A In vitro potency assay of radiolabeled and unlabeled CAR-T cells showed no significant difference in their IL-13Ra2 positive target tumor cell killing abilities in a co-culture assay as described in Materials and Methods. B Co-culture assay of labeled and unlabeled CAR-T effector cells with IL-13Ra2 positive U251, A172 and U87MG target cells showed similar values of IFN-y release in 20-h culture. IL-13Ra2 negative T98G glioma cells co-cultured with labeled and unlabeled CAR-T cells secreted basal amounts of IFN-y. A representative data of three independent experiments performed in quadruplicate is shown

Reference

 Leland P, Kumar D, Nimmagadda S, Bauer SR, Puri RK, Joshi BH. Characterization of chimeric antigen receptor modified T cells expressing scFv-lL-13Ra2 after radiolabeling with ⁸⁹Zirconium oxine for PET imaging. J Transl Med. 2023;21:367. https://doi.org/10.1186/s12967-023-04142-2.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.